Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has published a peer-reviewed study in Biomedicines demonstrating how its AI-powered PDAOAI platform helped identify a four-gene prognostic signature in hepatocellular carcinoma (HCC), the most common form of liver cancer. The study, published Oct. 23, 2026, used Partitioned Literature Aggregation (PLA), Oncotelic's patented algorithm running on PDAOAI, alongside gene-expression and survival analyses to pinpoint four genes: FKBP1A, EIF4E, RRAGC and PPARGC1A.
The signature's association with patient survival was independently validated in a Japanese HCC cohort of 203 patients. According to the company, the findings support patient stratification for clinical trials of Sapu003, an intravenous formulation of everolimus. This matters because HCC is a leading cause of cancer death worldwide, and reliable prognostic biomarkers are urgently needed to guide treatment decisions and improve trial success rates.
Oncotelic Chief Business Officer Saran Saund presented the research approach during an Oct. 22 keynote at the 22nd Drug Discovery Strategic Summit in California. The company highlighted the potential of partitioned AI investigations to uncover testable biological hypotheses and advance drug discovery. Oncotelic plans to expand PDAOAI toward a target scale of approximately 100 billion biological vectors for genetic and protein research.
Through its BIO REBOOT initiative, the company also invites researchers and development teams to submit projects for potential funding and support in validation, formulation, regulatory planning and clinical development, subject to scientific review and available resources. To view the full press release, visit https://ibn.fm/ctJ4J.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions.
The study's publication in a peer-reviewed journal lends credibility to Oncotelic's AI-driven approach, which could accelerate the identification of biomarkers and therapeutic targets across oncology. For investors and industry observers, the validation of the four-gene signature in an independent cohort represents a step toward more precise clinical trial design and potentially faster development of targeted therapies for liver cancer.
